Thomas is a cardiologist who earned his degree in Medicine and Computer Science at Heidelberg University and University of Paris with further training in Cardiology at the University Hospital in Geneva. He later spent seven years at the University of California, San Diego, as Assistant Professor of Medicine and Cardiovascular Associate. Subsequently, during his nine years at F. Hoffmann-La Roche, he was responsible for the worldwide clinical development of the company's cardiovascular portfolio.
In 1997, Thomas co-founded Actelion Pharmaceuticals Ltd., Europe’s largest biopharmaceutical company and was the company’s first Chief Executive Officer. He was instrumental in Actelion’s highly successful IPO and Secondary Offering after only three years of incorporation. He continues to serve on various Actelion boards worldwide.
In early 2017, Actelion’s active business was acquired by Johnson & Johnson for USD 30 billion and Actelion’s R&D pipeline transferred to a newly created company in Basel, “Idorsia Pharmaceuticals Ltd.”. Thomas is actively involved in Idorsia by setting up Idorsia's Asian business.
Thomas is a seasoned entrepreneur in the Life Science business having established several successful companies, in addition to Actelion. He has a understanding of the global drug research and development process as well as the industry's place in today's international and political health care environment.
Thomas travels internationally and mainly divides his time between Switzerland, New York, and Asia. He serves on the Boards of several biotech companies as well as on the Board of Trustees of the Paul & Daisy Soros Foundation and the New York Philharmonic Orchestra. He is married to Allyson Tang, Board Director of New York City Ballet, National Dance Institute, and Founder of the Angel Shine Foundation, a global philanthropic nonprofit organization.